BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 16158069)

  • 1. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
    Chen X; Cass JD; Bradley JA; Dahm CM; Sun Z; Kadyszewski E; Engwall MJ; Zhou J
    Br J Pharmacol; 2005 Nov; 146(6):792-9. PubMed ID: 16158069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.
    Watson KJ; Gorczyca WP; Umland J; Zhang Y; Chen X; Sun SZ; Fermini B; Holbrook M; Van Der Graaf PH
    J Pharmacol Toxicol Methods; 2011; 63(3):304-13. PubMed ID: 21419854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs.
    Ollerstam A; Visser SA; Duker G; Forsberg T; Persson AH; Nilsson LB; Björkman JA; Gabrielsson J; Al-Saffar A
    J Pharmacol Toxicol Methods; 2007; 56(2):131-44. PubMed ID: 17689270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A highly sensitive canine telemetry model for detection of QT interval prolongation: studies with moxifloxacin, haloperidol and MK-499.
    Chaves AA; Zingaro GJ; Yordy MA; Bustard KA; O'Sullivan S; Galijatovic-Idrizbegovic A; Schuck H; Christian DB; Hoe CM; Briscoe RJ
    J Pharmacol Toxicol Methods; 2007; 56(2):103-14. PubMed ID: 17643323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of probucol, a typical hERG expression inhibitor, on in vivo QT interval prolongation in conscious dogs.
    Nogawa H; Kawai T; Yajima M; Miura M; Ogawa T; Murakami K
    Eur J Pharmacol; 2013 Nov; 720(1-3):29-37. PubMed ID: 24211675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block.
    Thomsen MB; Beekman JD; Attevelt NJ; Takahara A; Sugiyama A; Chiba K; Vos MA
    Br J Pharmacol; 2006 Dec; 149(8):1039-48. PubMed ID: 17088870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The canine Purkinje fiber: an in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis.
    Gintant GA; Limberis JT; McDermott JS; Wegner CD; Cox BF
    J Cardiovasc Pharmacol; 2001 May; 37(5):607-18. PubMed ID: 11336111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
    Eur J Pharmacol; 2006 Dec; 553(1-3):229-39. PubMed ID: 17054943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation.
    Chaves AA; Keller WJ; O'Sullivan S; Williams MA; Fitzgerald LE; McPherson HE; Goykhman D; Ward PD; Hoe CM; Mixson L; Briscoe RJ
    J Pharmacol Toxicol Methods; 2006; 54(2):150-8. PubMed ID: 16679034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.
    Holzgrefe HH; Cavero I; Buchanan LV; Gill MW; Durham SK
    J Pharmacol Toxicol Methods; 2007; 55(3):227-37. PubMed ID: 17097307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity of common marmosets to detect drug-induced QT interval prolongation: moxifloxacin case study.
    Komatsu R; Honda M; Holzgrefe HH; Kubo J; Yamada Y; Isobe T; Kimura K; Itoh T; Tamaoki N; Tabo M
    J Pharmacol Toxicol Methods; 2010; 61(3):271-6. PubMed ID: 20097298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability.
    Wisialowski T; Crimin K; Engtrakul J; O'Donnell J; Fermini B; Fossa AA
    J Pharmacol Exp Ther; 2006 Jul; 318(1):352-9. PubMed ID: 16614168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin-induced QT prolongation and torsades: an uncommon effect of a common drug.
    Badshah A; Janjua M; Younas F; Halabi AR; Cotant JF
    Am J Med Sci; 2009 Aug; 338(2):164-6. PubMed ID: 19680025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks).
    Ducroq J; Moha ou Maati H; Guilbot S; Dilly S; Laemmel E; Pons-Himbert C; Faivre JF; Bois P; Stücker O; Le Grand M
    Br J Pharmacol; 2010 Jan; 159(1):93-101. PubMed ID: 19703166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics.
    Anderson ME; Mazur A; Yang T; Roden DM
    J Pharmacol Exp Ther; 2001 Mar; 296(3):806-10. PubMed ID: 11181910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beat-by-beat QT interval variability, but not QT prolongation per se, predicts drug-induced torsades de pointes in the anaesthetised methoxamine-sensitized rabbit.
    Jacobson I; Carlsson L; Duker G
    J Pharmacol Toxicol Methods; 2011; 63(1):40-6. PubMed ID: 20451633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil.
    Fossa AA; Langdon G; Couderc JP; Zhou M; Darpo B; Wilson F; Wallis R; Davis JD
    Clin Pharmacol Ther; 2011 Sep; 90(3):449-54. PubMed ID: 21814193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of injectable HPβCD-diclofenac on the human delayed rectifier potassium channel current in vitro and on proarrhythmic QTc in vivo.
    Carr DB; McDonnell Moorehead T; Bouchard A; Sprenger CR; Hamilton DA; Lang E; Madden D; Lacouture PG; Wright C
    Clin Ther; 2013 May; 35(5):646-58. PubMed ID: 23578606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation.
    Lu HR; Vlaminckx E; Van de Water A; Rohrbacher J; Hermans A; Gallacher DJ
    Eur J Pharmacol; 2007 Dec; 577(1-3):222-32. PubMed ID: 18074444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human.
    Parkinson J; Visser SA; Jarvis P; Pollard C; Valentin JP; Yates JW; Ewart L
    J Pharmacol Toxicol Methods; 2013; 68(3):357-66. PubMed ID: 23567074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.